Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 2
2005 3
2006 5
2007 3
2008 2
2009 2
2011 1
2012 4
2013 1
2014 8
2015 4
2016 2
2017 4
2018 4
2019 6
2020 4
2021 7
2022 8
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
A new national survey of centers for cognitive disorders and dementias in Italy.
Bacigalupo I, Giaquinto F, Salvi E, Carnevale G, Vaccaro R, Matascioli F, Remoli G, Vanacore N, Lorenzini P; Permanent Table of the National Dementia Plan Study Group and the CCDDs Study Group. Bacigalupo I, et al. Among authors: lorenzini p. Neurol Sci. 2024 Feb;45(2):525-538. doi: 10.1007/s10072-023-06958-8. Epub 2023 Aug 18. Neurol Sci. 2024. PMID: 37592124 Free PMC article.
What is the impact of post-COVID-19 syndrome on health-related quality of life and associated factors: a cross-sectional analysis.
Mastrorosa I, Del Duca G, Pinnetti C, Lorenzini P, Vergori A, Brita AC, Camici M, Mazzotta V, Baldini F, Chinello P, Mencarini P, Giancola ML, Abdeddaim A, Girardi E, Vaia F, Antinori A. Mastrorosa I, et al. Among authors: lorenzini p. Health Qual Life Outcomes. 2023 Mar 22;21(1):28. doi: 10.1186/s12955-023-02107-z. Health Qual Life Outcomes. 2023. PMID: 36949439 Free PMC article.
Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study).
Mastrorosa I, Gagliardini R, Segala FV, Mondi A, Lorenzini P, Cerva C, Taddei E, Bai F, Vergori A, Marcantonio N, Pinnetti C, Cicalini S, Murri R, Mazzotta V, Camici M, Mosti S, Bini T, Maffongelli G, Beccacece A, Milozzi E, Iannetta M, Lamonica S, Fusto M, Plazzi MM, Ottou S, Lichtner M, Fantoni M, Andreoni M, Sarmati L, Cauda R, Girardi E, Nicastri E, D'Arminio Monforte A, Palmieri F, Cingolani A, Vaia F, Antinori A; ESCAPE study group. Mastrorosa I, et al. Among authors: lorenzini p. EClinicalMedicine. 2023 Mar 10;57:101895. doi: 10.1016/j.eclinm.2023.101895. eCollection 2023 Mar. EClinicalMedicine. 2023. PMID: 36936403 Free PMC article.
Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failures.
Gagliardini R, Lorenzini P, Cozzi-Lepri A, Tavelli A, Borghi V, Galli L, Tagliaferri G, Maggiolo F, Mussini C, Castagna A, Monforte AD, Antinori A. Gagliardini R, et al. Among authors: lorenzini p. J Glob Antimicrob Resist. 2023 Mar;32:158-163. doi: 10.1016/j.jgar.2022.11.010. Epub 2022 Nov 17. J Glob Antimicrob Resist. 2023. PMID: 36402369 Free article.
The Italian fund for Alzheimer's and other dementias: strategies and objectives to face the dementia challenge.
Ancidoni A, Sciancalepore F, Bacigalupo I, Bellomo G, Canevelli M, Lacorte E, Lombardo FL, Lorenzini P, Palazzesi I, Piscopo P, Salvi E, Bianchi CBNA, Landoni F, La Sala L, Di Fiandra T, Vanacore N; Permanent Table of the National Dementia Plan Study Group; Istituto Superiore di Sanità FONDEM Study Group; Istituto Superiore di Sanità FONDEM StudyGroup. Ancidoni A, et al. Among authors: lorenzini p. Ann Ist Super Sanita. 2022 Jul-Sep;58(3):192-196. doi: 10.4415/ANN_22_03_08. Ann Ist Super Sanita. 2022. PMID: 36128968 Free article.
Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV.
Vergori A, Cozzi Lepri A, Cicalini S, Matusali G, Bordoni V, Lanini S, Meschi S, Iannazzo R, Mazzotta V, Colavita F, Mastrorosa I, Cimini E, Mariotti D, De Pascale L, Marani A, Gallì P, Garbuglia A, Castilletti C, Puro V, Agrati C, Girardi E, Vaia F, Antinori A; HIV-VAC study group. Vergori A, et al. Nat Commun. 2022 Aug 22;13(1):4922. doi: 10.1038/s41467-022-32263-7. Nat Commun. 2022. PMID: 35995780 Free PMC article.
Declining Prevalence of Human Immunodeficiency Virus (HIV)-Associated Neurocognitive Disorders in Recent Years and Associated Factors in a Large Cohort of Antiretroviral Therapy-Treated Individuals With HIV.
Mastrorosa I, Pinnetti C, Brita AC, Mondi A, Lorenzini P, Del Duca G, Vergori A, Mazzotta V, Gagliardini R, Camici M, De Zottis F, Fusto M, Plazzi MM, Grilli E, Bellagamba R, Cicalini S, Antinori A. Mastrorosa I, et al. Among authors: lorenzini p. Clin Infect Dis. 2023 Feb 8;76(3):e629-e637. doi: 10.1093/cid/ciac658. Clin Infect Dis. 2023. PMID: 35982541 Free PMC article.
SARS-CoV-2 Specific Immune Response and Inflammatory Profile in Advanced HIV-Infected Persons during a COVID-19 Outbreak.
Vergori A, Boschini A, Notari S, Lorenzini P, Castilletti C, Colavita F, Matusali G, Tartaglia E, Gagliardini R, Boschi A, Cimini E, Maeurer M, Piselli P, Angeli L, Antinori A, Agrati C, Girardi E. Vergori A, et al. Among authors: lorenzini p. Viruses. 2022 Jul 20;14(7):1575. doi: 10.3390/v14071575. Viruses. 2022. PMID: 35891555 Free PMC article.
Virological and Immunological Outcomes of an Intensified Four-Drug versus a Standard Three-Drug Antiretroviral Regimen, Both Integrase Strand Transfer Inhibitor-Based, in Primary HIV Infection.
Mondi A, Pinnetti C, Lorenzini P, Plazzi MM, Abbate I, Camici M, Agrati C, Grilli E, Gili F, Esvan R, Orchi N, Rozera G, Amendola A, Forbici F, Gori C, Gagliardini R, Bellagamba R, Ammassari A, Cicalini S, Capobianchi MR, Antinori A. Mondi A, et al. Among authors: lorenzini p. Pharmaceuticals (Basel). 2022 Mar 26;15(4):403. doi: 10.3390/ph15040403. Pharmaceuticals (Basel). 2022. PMID: 35455400 Free PMC article.
Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count.
Antinori A, Cicalini S, Meschi S, Bordoni V, Lorenzini P, Vergori A, Lanini S, De Pascale L, Matusali G, Mariotti D, Cozzi Lepri A, Gallì P, Pinnetti C, Gagliardini R, Mazzotta V, Mastrorosa I, Grisetti S, Colavita F, Cimini E, Grilli E, Bellagamba R, Lapa D, Sacchi A, Marani A, Cerini C, Candela C, Fusto M, Puro V, Castilletti C, Agrati C, Girardi E, Vaia F; HIV-VAC Study Group. Antinori A, et al. Among authors: lorenzini p. Clin Infect Dis. 2022 Aug 24;75(1):e552-e563. doi: 10.1093/cid/ciac238. Clin Infect Dis. 2022. PMID: 35366316 Free PMC article.
76 results